Research graph
References from ESR1 and PIK3CA circulating tumor DNA (ctDNA) mutation status as predictive biomarkers beyond variant allele fraction (VAF) in metastatic breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Circulating tumor DNA in breast cancer: from technological foundation to clinical implementation
10.1016/j.ctrv.2026.103108 · 2026 · External reference
Unresolved reference
2025 · External reference
The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer
2026 · External reference
Liquid biopsy: cell-free DNA based analysis in breast cancer
10.1016/j.jlb.2023.100002 · 2023 · External reference
Variant allele frequency: a decision-making tool in precision oncology?
10.1016/j.trecan.2023.08.011 · 2023 · External reference
Circulating tumor DNA in breast cancer: a biomarker for patient selection
10.1097/cco.0000000000000964 · 2023 · External reference
Cell-free circulating tumor DNA variant allele frequency associates with survival in metastatic cancer
10.1158/1078-0432.ccr-19-0306 · 2020 · External reference
Driver mutation variant allele frequency in circulating tumor DNA and association with clinical outcome in patients with non-small cell lung cancer and EGFR- and KRAS-mutated tumors
10.1016/j.jmoldx.2022.02.002 · 2022 · External reference
Variant allele frequency analysis of circulating tumor DNA as a promising tool in assessing the effectiveness of treatment in non-small cell lung carcinoma patients
10.3390/cancers16040782 · 2024 · External reference
ESR1 mutations in HR+/HER2-metastatic breast cancer: enhancing the accuracy of ctDNA testing
10.1016/j.ctrv.2023.102642 · 2023 · External reference
Integrating PIK3CA testing into clinical practice for advanced HR+/HER2- breast cancer: an expert consensus
10.1016/j.breast.2026.104786 · 2026 · External reference
Harmonizing definitions in liquid biopsy: a terminology framework by the international society of liquid biopsy
10.1016/j.jlb.2026.100462 · 2026 · External reference
10.1016/j.csbj.2019.10.004 · 2019 · Admitted local publication
Part II - analytical phase
10.32074/1591-951x-1216 · 2025 · External reference
Using high-resolution variant frequencies to empower clinical genome interpretation
10.1038/gim.2017.26 · 2017 · External reference
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors
10.1002/1878-0261.13557 · 2024 · External reference
What the VAF? A guide to the interpretation of variant allele fraction, percent mosaicism, and copy number in cancer
10.1186/s13039-025-00718-3 · 2025 · External reference
Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice
10.1038/s41598-026-40923-7 · 2026 · External reference
New opportunities and challenges for nonshedder tumors
10.1016/j.fmre.2025.12.002 · 2026 · External reference
Breast cancer with bone metastasis: molecular insights and clinical management
10.3390/cells10061377 · 2021 · External reference
Breast cancer with brain metastasis: molecular insights and clinical management
10.3390/genes14061160 · 2023 · External reference
Exploring treatment options in cancer: tumor treatment strategies
10.1038/s41392-024-01856-7 · 2024 · External reference
International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors
10.1016/j.jlb.2025.100301 · 2025 · External reference
Role of the International Society of Liquid Biopsy (ISLB) in establishing quality control frameworks for clinical integration
10.1016/j.critrevonc.2025.104619 · 2025 · External reference
Systemic inflammation induces release of cell-free DNA from hematopoietic and parenchymal cells in mice and humans
10.1182/bloodadvances.2018018895 · 2019 · External reference
The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA
10.1002/1878-0261.12729 · 2020 · External reference
Cell-free DNA: a promising biomarker in infectious diseases
10.1016/j.tim.2024.06.005 · 2025 · External reference
Laboratory practices for next-generation sequencing-based circulating tumor DNA analysis: insights from a comprehensive survey in China
10.1007/s00428-025-04156-9 · 2026 · External reference
Prediction model for ctDNA detectability in liquid comprehensive genomic profiling of advanced pancreatic cancer based on Japanese real-world data
10.1016/j.esmoop.2026.106069 · 2026 · External reference
Timing of ctDNA analysis aimed at guiding adjuvant treatment in colorectal cancer
10.1158/1078-0432.ccr-24-3200 · 2025 · External reference
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
10.1016/j.annonc.2025.11.002 · 2026 · External reference
Clinicogenomic landscape and function of PIK3CA, AKT1, and PTEN mutations in breast cancer
10.1200/po-25-00609 · 2026 · External reference
PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer
10.3389/fonc.2021.644737 · 2021 · External reference
Drugging the PI3K/AKT/mTOR pathway in ER+ breast cancer
10.3390/ijms24054522 · 2023 · External reference
Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2- metastatic breast cancer
10.32074/1591-951x-1531 · 2025 · External reference
ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer
10.1080/14737159.2025.2576021 · 2025 · External reference
Harmonization trial on ESR1 testing strategies in ER+/HER2- breast cancer patients: an Italian experience
10.1016/j.jlb.2025.100314 · 2025 · External reference
ESR1 analysis of liquid biopsy in breast cancer, one-year routine experience of an Italian clinical referral center
10.1016/j.jlb.2025.100331 · 2025 · External reference
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-Positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: results from the randomized phase III EMERALD trial
10.1200/jco.22.00338 · 2022 · External reference
Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-Mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups
10.1158/1078-0432.ccr-24-1073 · 2024 · External reference
Real-time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: feasibility and cross-validation with NGS
10.1021/acs.analchem.2c00446 · 2022 · External reference
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising <em>ESR1</em> mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
10.1016/s1470-2045(22)00555-1 · 2022 · External reference
The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6
10.1007/s10549-025-07839-8 · 2025 · External reference
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine
10.1038/s41571-025-01066-2 · 2025 · External reference
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment
10.2217/fon-2022-1196 · 2023 · External reference
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
10.1016/s1470-2045(21)00034-6 · 2021 · External reference
Overall survival with Inavolisib in PIK3CA-Mutated advanced breast cancer
10.1056/nejmoa2501796 · 2025 · External reference
Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial
10.1007/s12282-024-01640-z · 2025 · External reference
